Catalyst Wire Dossier Catalyst Wire Dossier

Penpulimab (AK105)

penpulimab · Akeso Biopharma
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Penpulimab (AK105), covering 2025-04-13 to 2025-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

See pricing